Kymera Therapeutics, Inc. SEC Filings

A stockholder of Kymera Therapeutics (KYMR) filed a Form 144 notice to sell 5,500 common shares through Morgan Stanley Smith Barney LLC on or about 01/20/2026. The shares were acquired the same day by exercising stock options for cash, and the planned sale has an aggregate market value of $382,470.00. Kymera had 71,949,027 shares outstanding at the time referenced.

The filing also reports that, during the prior three months, there were Rule 10b5-1 sales for Pamela Esposito of 27,563 common shares on 12/17/2025, generating $2,264,479.00 in gross proceeds. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Kymera’s operations.

Kymera Therapeutics, Inc. reported a preliminary estimate of approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025. These figures are unaudited, form part of its fourth-quarter and full-year 2025 results, and may change as the year-end audit is completed.

The company also provided a business update and outlined its key 2026 objectives and strategy to advance its leading portfolio of immunology programs in a press release furnished as Exhibit 99.1. Kymera plans to discuss these topics in meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference.

FMR LLCAbigail P. Johnson report beneficial ownership of 8,928,574.12 shares of Kymera Therapeutics Inc. common stock, representing 11.2% of the outstanding class as of the event date. FMR LLC has sole voting power over 8,921,331 shares and sole dispositive power over 8,928,574.12 shares, while Abigail P. Johnson has sole dispositive power over the same 8,928,574.12 shares and no voting power.

The securities are certified as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Kymera Therapeutics. The filing notes that one or more other persons have rights to dividends or sale proceeds for these shares, but no single such person has an interest exceeding five percent of the company’s common stock.

Kymera Therapeutics Chief Executive Officer Nello Mainolfi reported an option exercise involving company stock. On January 5, 2026, he exercised a stock option to acquire 3,118 shares of Kymera Therapeutics common stock at an exercise price of $32.07 per share, reflected as an option exercise (code M). Following this transaction, he directly holds 666,195 shares of common stock and 446,882 stock options in total.

The option exercised relates to a grant whose underlying shares vest in 36 equal monthly installments starting on March 1, 2023, and the vesting continues only if he remains employed through each vesting date. This filing shows a routine equity compensation transaction by Kymera Therapeutics’ CEO, combining ongoing vesting with a partial option exercise.

Kymera Therapeutics, Inc. reported an insider equity transaction by its Chief Executive Officer, who is also a director. On 12/31/2025, the reporting person exercised a stock option for 30,000 shares of common stock at an exercise price of $2.08 per share and acquired those shares. On the same date, the reporting person sold a total of 30,000 shares of common stock in two transactions: 23,986 shares at a weighted average price of $77.9508 and 6,014 shares at a weighted average price of $78.5187, all pursuant to a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person beneficially owned 663,077 shares of common stock directly and 275,559 derivative securities (stock options), with the option relating to these 30,000 shares fully vested and exercisable.

Kymera Therapeutics, Inc. reported an insider stock option exercise by its Chief Executive Officer and director on 12/17/2025. The CEO exercised a stock option to acquire 2,595 shares of common stock at an exercise price of $38.53 per share. Following this transaction, he beneficially owns 663,077 shares of common stock directly.

The exercised option was a stock option (right to buy) covering 2,595 shares of common stock, with an exercise price of $38.53 and an expiration date of 03/01/2032. After the transaction, 272,505 derivative securities (stock options) remain beneficially owned directly. The filing notes that the shares underlying this stock option are fully vested and exercisable.

Kymera Therapeutics, Inc. director reports option exercises and stock sales. On 12/17/2025, the reporting person, a director of Kymera Therapeutics (KYMR), exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2025.

The director exercised options for 12,563 shares at $49.10, 12,000 shares at $27.67, and 3,000 shares at $31.20, acquiring a total of 27,563 common shares. On the same date, they sold 14,505 shares at a weighted average price of $81.557, 7,959 shares at $82.3422, 4,099 shares at $83.4507, and 1,000 shares at $84.07, leaving 0 directly owned common shares.

Following these transactions, the director continued to hold stock options, including 7,500 options with a $49.10 exercise price expiring on June 15, 2031, and 13,000 options with a $31.20 exercise price expiring on June 18, 2034. All underlying option shares were reported as fully vested and exercisable.

Kymera Therapeutics, Inc. reported insider activity showing that a director, filing individually, completed multiple sales of Kymera common stock on December 10–12, 2025 through affiliated investment funds. The transactions involved several blocks of common stock sold at weighted average prices including $88.64, $89.25, $90.14, $92.41, $93.20, $91.23 and $91.04 per share, with underlying trade prices ranging from $88.00 to about $93.69 per share as described in the footnotes.

After these sales, Atlas Venture Fund X, L.P. held 3,974,481 Kymera shares and Atlas Venture Opportunity Fund I, L.P. held 685,393 shares, reported as indirectly beneficially owned by the director through general partner entities. The director disclaims beneficial ownership of these fund-held securities except to the extent of any pecuniary interest.

Kymera Therapeutics, Inc. reported insider purchases by affiliated Baker Brothers funds in a public stock offering that closed on December 11, 2025. Investment fund 667, L.P. bought 167,192 shares of Kymera common stock, and Baker Brothers Life Sciences, L.P. bought 1,838,621 shares, each at a price to the public of $86.00 per share in an underwritten offering.

After these transactions, 667 is listed as beneficially owning 701,326 Kymera shares and Life Sciences 7,955,916 shares, held indirectly through their partnership structures. The reporting group includes Baker Bros. Advisors LP, its general partner, and Julian C. Baker and Felix J. Baker, who describe advisory and partnership arrangements and disclaim beneficial ownership beyond their pecuniary interest. Felix J. Baker serves on Kymera’s board, and the other reporting persons are treated as directors by deputization due to this board representation.